CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
JNJ-73763989 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04585789
NCT04585789Phase 2Completed
CompareCT.gov

A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)Ide Analog With or Without JNJ-56136379 in Patients With Chronic Hepatitis B Virus Infection

Janssen Research & Development, LLC·interventional·Posted Oct 14, 2020·Updated May 21, 2025

In Brief

A Phase 2 clinical trial evaluating JNJ-73763989, JNJ-56136379, and 4 other interventions for Hepatitis B. Completed, enrolled 24 participants across 10 sites in 9 countries.

Detailed Summary

The purpose of this study is to assess changes in intrahepatic hepatitis B surface antigen (HBsAg) between baseline and on-treatment liver biopsy in response to JNJ-3989-based combination treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B
CountriesBelgium, Canada, France, Germany, Italy, New Zealand, Poland, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedOct 14, 2020
Enrollment StartMar 11, 2021
Primary CompletionFeb 8, 2023
Study CompletionJan 9, 2024
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 5.7 years ago

Interventions

JNJ-73763989drug

JNJ-73763989 will be administered subcutaneously once every 4 weeks up to Week 44.

JNJ-56136379drug

JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.

Entecavir (ETV)drug

ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.

Tenofovir disoproxildrug

Tenofovir disoproxil will be administered orally once daily up to 48 weeks as NA treatment.

Tenofovir alafenamide (TAF)drug

TAF will be administered orally once daily up to 48 weeks as NA treatment.

PegIFN-alpha-2a (Optional)drug

PegIFN-alpha-2a injection will be administered subcutaneously once weekly after Week 40 for either 12 or 24 weeks.